This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2000 Dec;23(3):239-40.

doi: 10.1016/s0955-3886(00)00092-8.

The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)

V Berdoukas¹, T Bohane, C Eagle, R Lindeman, K DeSilva, V Tobias, D Painter, I Fraser

Affiliations

PMID: 11099900
DOI: 10.1016/s0955-3886(00)00092-8

The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)

V Berdoukas et al. Transfus Sci. 2000 Dec.

. 2000 Dec;23(3):239-40.

doi: 10.1016/s0955-3886(00)00092-8.

Authors

V Berdoukas¹, T Bohane, C Eagle, R Lindeman, K DeSilva, V Tobias, D Painter, I Fraser

Affiliation

¹ Sydney Children's Hospital, Sydney, Australia.

PMID: 11099900
DOI: 10.1016/s0955-3886(00)00092-8

No abstract available

PubMed Disclaimer

Similar articles

Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience.
Chuansumrit A, Songdej D, Sirachainan N, Wongwerawattanakoon P, Kadegasem P, Sasanakul W. Chuansumrit A, et al. Paediatr Int Child Health. 2016 Aug;36(3):209-13. doi: 10.1179/2046905515Y.0000000040. Epub 2016 Jan 29. Paediatr Int Child Health. 2016. PMID: 26052612
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F. Taher A, et al. Eur J Haematol. 2001 Jul;67(1):30-4. doi: 10.1034/j.1600-0609.2001.067001030.x. Eur J Haematol. 2001. PMID: 11553264 Clinical Trial.
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A. Kontoghiorghes GJ, et al. Transfus Sci. 2000 Dec;23(3):211-23. doi: 10.1016/s0955-3886(00)00089-8. Transfus Sci. 2000. PMID: 11099897 Review.
Deferiprone approved for iron overload.
Traynor K. Traynor K. Am J Health Syst Pharm. 2011 Nov 15;68(22):2106. doi: 10.2146/news110073. Am J Health Syst Pharm. 2011. PMID: 22058092 No abstract available.
Pharmacotherapy of iron overload in thalassaemic patients.
Ceci A, Felisi M, De Sanctis V, De Mattia D. Ceci A, et al. Expert Opin Pharmacother. 2003 Oct;4(10):1763-74. doi: 10.1517/14656566.4.10.1763. Expert Opin Pharmacother. 2003. PMID: 14521486 Review.

See all similar articles

Cited by

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ. Fisher SA, et al. Cochrane Database Syst Rev. 2013 Aug 21;2013(8):CD004450. doi: 10.1002/14651858.CD004450.pub3. Cochrane Database Syst Rev. 2013. PMID: 23963793 Free PMC article.
Oral deferiprone for iron chelation in people with thalassaemia.
Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ. Fisher SA, et al. Cochrane Database Syst Rev. 2013 Aug 21;2013(8):CD004839. doi: 10.1002/14651858.CD004839.pub3. Cochrane Database Syst Rev. 2013. PMID: 23966105 Free PMC article.
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
Kontoghiorghes GJ, Neocleous K, Kolnagou A. Kontoghiorghes GJ, et al. Drug Saf. 2003;26(8):553-84. doi: 10.2165/00002018-200326080-00003. Drug Saf. 2003. PMID: 12825969 Review.
Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
Olivieri NF, Sabouhanian A, Gallie BL. Olivieri NF, et al. PLoS One. 2019 Feb 27;14(2):e0211942. doi: 10.1371/journal.pone.0211942. eCollection 2019. PLoS One. 2019. PMID: 30811439 Free PMC article.
Friedreich ataxia-update on pathogenesis and possible therapies.
Voncken M, Ioannou P, Delatycki MB. Voncken M, et al. Neurogenetics. 2004 Feb;5(1):1-8. doi: 10.1007/s10048-003-0170-z. Epub 2003 Dec 19. Neurogenetics. 2004. PMID: 14689254 Review.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science